First patient dosed in TopoTargets randomized BelCaP study in CUP (Carcinoma of Unknown Primary site)

Announcement No. 11-09 / Copenhagen, 16 April 2009	

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

- Randomized phase II study of belinostat in combination with carboplatin and
paclitaxel (BelCaP) compared to carboplatin and paclitaxel initiated in solid
tumors 
(Carcinoma of Unknown Primary site; CUP) -


Copenhagen, Denmark - 16 April 2009 - TopoTarget A/S (OMX: TOPO) has announced
that the first patient has been dosed in an open label randomized phase II
study of belinostat in combination with carboplatin and paclitaxel (BelCaP)
compared to carboplatin and paclitaxel in patients with previously untreated
CUP. The study aims to demonstrate the efficacy of belinostat in solid tumors
in a randomized setting. Approximately 44 patients will be randomized to each
group, in total 88 patients. 


“We are proud to collaborate with key CUP opinion leaders both in the US and in
Europe on this trial aimed to improve the progression free survival of patients
suffering from CUP. We have previously demonstrated very promising results in
platinum-resistant ovarian cancer when adding full dose belinostat to the
combination of carboplatin and paclitaxel - the so-called BelCaP combination.
Carboplatin and paclitaxel is also a first time standard of care in CUP and we
can now directly evaluate the effect of adding belinostat” says professor Peter
Buhl Jensen, CEO of TopoTarget. 

  
Carcinoma of Unknown Primary site (CUP) represents a solid tumor type that is
defined by the presence of metastases (where the cancer has spread to other
parts of the body) at first presentation for which a primary site cannot be
determined after defined diagnostic procedures. 

TopoTarget A/S

For further information, please contact:

Peter Buhl Jensen	Telephone	+45 39 17 94 99
CEO		Mobile	+45 21 60 89 22